Development of a virus-mimicking nanocarrier for drug delivery systems: The bio-nanocapsule

Advanced Drug Delivery Reviews

Volumn 95, Issue , 2015, Pages 77-89

  Somiya, Masaharu ^a,b,c   Kuroda, Shun'ichi ^a,b  

^a OSAKA UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

^c JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

Author keywords

Active targeting; Biomimicking; Hepatitis B virus; Liposome; Membrane fusion; Virus like particle

Indexed keywords

BIOMIMETICS; CELL MEMBRANES; CHEMICAL MODIFICATION; CONTROLLED DRUG DELIVERY; CYTOLOGY; LIPOSOMES; NANOCAPSULES; NUCLEIC ACIDS; PROTEINS; VIRUSES;

ACTIVE TARGETING; BIO-MIMICKING; HEPATITIS B VIRUS; MEMBRANE FUSION; VIRUS-LIKE PARTICLES;

TARGETED DRUG DELIVERY;

LIPOSOME; NANOCAPSULE; NANOCARRIER; VIROSOME; VIRUS ENVELOPE PROTEIN; BIOMIMETIC MATERIAL; L PROTEIN, HEPATITIS B VIRUS;

ARTICLE; CHEMICAL MODIFICATION; COMPLEX FORMATION; DRUG DELIVERY SYSTEM; ELECTROPORATION; GENE FUSION; HEPATITIS B VIRUS; HUMAN; LIVER CELL; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS ENVELOPE; VIRUS PARTICLE; ANIMAL;

ANIMALS; BIOMIMETIC MATERIALS; DRUG DELIVERY SYSTEMS; HEPATITIS B VIRUS; HUMANS; NANOCAPSULES; VIRAL ENVELOPE PROTEINS;

EID: 84954471299     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.10.003     Document Type: Review

References (111)

1. Zhang Y., Chan H.F., Leong K.W. Advanced materials and processing for drug delivery: the past and the future. Adv. Drug Deliv. Rev. 2013, 65:104-120. 10.1016/j.addr.2012.10.003.
2. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2:751-760. 10.1038/nnano.2007.387.
3. Brannon-Peppas L., Blanchette J.O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 2012, 64:206-212. 10.1016/j.addr.2012.09.033.
4. Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994, 54:987-992.
5. Barenholz Y. Doxil-the first FDA-approved nano-drug: lessons learned. J. Control. Release 2012, 160:117-134. 10.1016/j.jconrel.2012.03.020.
6. Cabral H., Kataoka K. Progress of drug-loaded polymeric micelles into clinical studies. J. Control. Release 2014, 190:465-476. 10.1016/j.jconrel.2014.06.042.
7. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4:145-160. 10.1038/nrd1632.
8. Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 2009, 8:129-138. 10.1038/nrd2742.
9. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cnacer chemotherapy: mechanism of tumoritropic accumulatio of proteins and the antitumor agents Smancs. Cancer Res. 1986, 46:6387-6392. (http://cancerres.aacrjournals.org/content/46/12_Part_1/6387.short (accessed January 22, 2015)).
10. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzym. Regul. 2001, 41:189-207. (http://www.ncbi.nlm.nih.gov/pubmed/11384745).
11. Maeda H., Sawa T., Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control. Release 2001, 74:47-61. 10.1016/S0168-3659(01)00309-1.
12. Maeda H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv. Drug Deliv. Rev. 2015, 91:3-6. 10.1016/j.addr.2015.01.002.
13. Jain R.K. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 1990, 50.
14. Qian Z.M., Li H., Sun H., Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev. 2002, 54:561-587. 10.1124/pr.54.4.561.
15. Teng L., Xie J., Teng L., Lee R.J. Clinical translation of folate receptor-targeted therapeutics. Expert Opin. Drug Deliv. 2012, 9:901-908. 10.1517/17425247.2012.694863.
16. Heidel J.D., Yu Z., Liu J.Y.-C., Rele S.M., Liang Y., Zeidan R.K., et al. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:5715-5721. 10.1073/pnas.0701458104.
17. Davis M.E., Zuckerman J.E., Choi C.H.J., Seligson D., Tolcher A., Alabi C.A., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070. 10.1038/nature08956.
18. Germershaus O., Merdan T., Bakowsky U., Behe M., Kissel T. Trastuzumab-polyethylenimine-polyethylene glycol conjugates for targeting Her2-expressing tumors. Bioconjug. Chem. 2006, 17:1190-1199. 10.1021/bc0601119.
19. Kanasty R., Dorkin J.R., Vegas A., Anderson D. Delivery materials for siRNA therapeutics. Nat. Mater. 2013, 12:967-977. 10.1038/nmat3765.
20. Schneider-Schaulies J. Cellular receptors for viruses: links to tropism and pathogenesis. J. Gen. Virol. 2000, 81:1413-1429.
21. Tiollais P., Pourcel C., Dejean A. The hepatitis B virus. Nature 1985, 317:489-495. 10.1038/317489a0.
22. Valenzuela P., Medina A., Rutter W.J., Ammerer G., Hall B.D. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 1982, 298:347-350. 10.1038/298347a0.
23. Itoh Y., Fujisawa Y. Synthesis in yeast of hepatitis B virus surface antigen modified P31 particles by gene modification. Biochem. Biophys. Res. Commun. 1986, 141:942-948. 10.1016/S0006-291X(86)80134-6.
24. Kuroda S., Fujisawa Y., Iino S., Akahane Y., Suzuki H. Induction of protection level of anti-pre-S2 antibodies in humans immunized with a novel hepatitis B vaccine consisting of M (pre-S2+S) protein particles (a third generation vaccine). Vaccine 1991, 9:163-169.
25. Kuroda S., Otaka S., Miyazaki T., Nakao M., Fujisawa Y. Hepatitis B virus envelope L protein particles: synthesis and assembly in Saccharomyces cerevisiae, purification and characterization. J. Biol. Chem. 1992, 267:1953-1961. (http://www.ncbi.nlm.nih.gov/pubmed/18434744).
26. Jung J., Iijima M., Yoshimoto N., Sasaki M., Niimi T., Tatematsu K., et al. Efficient and rapid purification of drug- and gene-carrying bio-nanocapsules, hepatitis B virus surface antigen L particles, from Saccharomyces cerevisiae. Protein Expr. Purif. 2011, 78:149-155. 10.1016/j.pep.2011.04.008.
27. Yamada T., Iwabuki H., Kanno T., Tanaka H., Kawai T., Fukuda H., et al. Physicochemical and immunological characterization of hepatitis B virus envelope particles exclusively consisting of the entire L (pre-S1+pre-S2+S) protein. Vaccine 2001, 19:3154-3163. 10.1016/S0264-410X(01)00017-2.
28. Cossart Y.E., Field A.M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet 1970, 1:848. 10.1016/S0140-6736(70)92460-8.
29. Watashi K., Urban S., Li W., Wakita T. NTCP and beyond: opening the door to unveil hepatitis B virus entry. Int. J. Mol. Sci. 2014, 15:2892-2905. 10.3390/ijms15022892.
30. Neurath A.R., Kent S.B., Strick N., Parker K. Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell 1986, 46:429-436. doi:0092-8674(86)90663-X [pii].
31. Neurath A.R., Seto B., Strick N. Antibodies to synthetic peptides from the preS1 region of the hepatitis B virus (HBV) envelope (env) protein are virus-neutralizing and protective. Vaccine 1989, 7:234-236. 10.1016/0264-410X(89)90235-1.
32. Yamada T., Iwasaki Y., Tada H., Iwabuki H., Chuah M.K.L., VandenDriessche T., et al. Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nat. Biotechnol. 2003, 21:885-890. 10.1038/nbt843.
33. Iwasaki Y., Ueda M., Yamada T., Kondo A., Seno M., Tanizawa K., et al. Gene therapy of liver tumors with human liver-specific nanoparticles. Cancer Gene Ther. 2007, 14:74-81. 10.1038/sj.cgt.7701031.
34. Matsuura Y., Yagi H., Matsuda S., Itano O., Aiura K., Kuroda S., et al. Human liver-specific nanocarrier in a novel mouse xenograft model bearing noncancerous human liver tissue. Eur. Surg. Res. 2011, 46:65-72. 10.1159/000322491.
35. Schulze A., Gripon P., Urban S. Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology 2007, 46:1759-1768. 10.1002/hep.21896.
36. Salisse J., Sureau C. A function essential to viral entry underlies the hepatitis B virus "a" determinant. J. Virol. 2009, 83:9321-9328. 10.1128/JVI.00678-09.
37. Bernfield M., Götte M., Park P.W., Reizes O., Fitzgerald M.L., Lincecum J., et al. Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 1999, 68:729-777. 10.1146/annurev.biochem.68.1.729.
38. Yan H., Zhong G., Xu G., He W., Jing Z., Gao Z., et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 2012, 1. 10.7554/eLife.00049.
39. Iwamoto M., Watashi K., Tsukuda S., Aly H.H., Fukasawa M., Fujimoto A., et al. Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP. Biochem. Biophys. Res. Commun. 2014, 443:808-813. 10.1016/j.bbrc.2013.12.052.
40. Yan H., Peng B., He W., Zhong G., Qi Y., Ren B., et al. Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide. J. Virol. 2013, 87:7977-7991. 10.1128/JVI.03540-12.
41. Li H., Zhuang Q., Wang Y., Zhang T., Zhao J., Zhang Y., et al. HBV life cycle is restricted in mouse hepatocytes expressing human NTCP. Cell. Mol. Immunol. 2014, 11:175-183. 10.1038/cmi.2013.66.
42. Meier A., Mehrle S., Weiss T.S., Mier W., Urban S. Myristoylated PreS1-domain of the hepatitis B virus L-protein mediates specific binding to differentiated hepatocytes. Hepatology 2013, 58:31-42. 10.1002/hep.26181.
43. Yamada M., Oeda A., Jung J., Iijima M., Yoshimoto N., Niimi T., et al. Hepatitis B virus envelope L protein-derived bio-nanocapsules: mechanisms of cellular attachment and entry into human hepatic cells. J. Control. Release 2012, 160:322-329. 10.1016/j.jconrel.2011.11.004.
44. Kasuya T., Nomura S., Matsuzaki T., Jung J., Yamada T., Tatematsu K., et al. Expression of squamous cell carcinoma antigen-1 in liver enhances the uptake of hepatitis B virus envelope-derived bio-nanocapsules in transgenic rats. FEBS J. 2008, 275:5714-5724. 10.1111/j.1742-4658.2008.06698.x.
45. Harrison S.C. Viral membrane fusion. Nat. Struct. Mol. Biol. 2008, 15:690-698. 10.1038/nsmb.1456.
46. Baumert T.F., Meredith L., Ni Y., Felmlee D.J., McKeating J.A., Urban S. Entry of hepatitis B and C viruses-recent progress and future impact. Curr. Opin. Virol. 2014, 4:58-65. 10.1016/j.coviro.2013.12.002.
47. Oess S., Hildt E. Novel cell permeable motif derived from the PreS2-domain of hepatitis-B virus surface antigens. Gene Ther. 2000, 7:750-758. 10.1038/sj.gt.3301154.
48. Rodriguez-Crespo I., Gomez-Gutierrez J., Nieto M., Peterson D.L., Gavilanes F. Prediction of a putative fusion peptide in the S protein of hepatitis B virus. J. Gen. Virol. 1994, 75:637-639. 10.1099/0022-1317-75-3-637.
49. Somiya M., Sasaki Y., Matsuzaki T., Liu Q., Iijima M., Yoshimoto N., et al. Intracellular traficking of bio-nanocapsule-liposome complex: identification of fusogenic activity in the pre-S1 region of hepatitis B virus surface antigen L protein. J. Control. Release 2015, 212:10-18. 10.1016/j.jconrel.2015.06.012.
50. Krone B., Lenz A., Heermann K.H., Seifer M., Lu X.Y., Gerlich W.H. Interaction between hepatitis B surface proteins and monomeric human serum albumin. Hepatology 1990, 11:1050-1056. (http://www.ncbi.nlm.nih.gov/pubmed/2163967).
51. Ishihara K., Waters J.A., Pignatelli M., Thomas H.C. Characterisation of the polymerised and monomeric human serum albumin binding sites on hepatitis B surface antigen. J. Med. Virol. 1987, 21:89-95. (http://www.ncbi.nlm.nih.gov/pubmed/3794674).
52. Itoh Y., Kuroda S., Miyazaki T., Otaka S., Fujisawa Y. Identification of polymerized-albumin receptor domain in the pre-S2 region of hepatitis B virus surface antigen M protein. J. Biotechnol. 1992, 23:71-82. 10.1016/0168-1656(92)90100-N.
53. Dams E.T., Laverman P., Oyen W.J., Storm G., Scherphof G.L., van Der Meer J.W., et al. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J. Pharmacol. Exp. Ther. 2000, 292:1071-1079.
54. Nagaoka T., Fukuda T., Yoshida S., Nishimura H., Yu D., Kuroda S., et al. Characterization of bio-nanocapsule as a transfer vector targeting human hepatocyte carcinoma by disulfide linkage modification. J. Control. Release 2007, 118:348-356. 10.1016/j.jconrel.2006.12.020.
55. Kobayashi M., Asano T., Utsunomiya M., Itoh Y., Fujisawa Y., Nishimura O., et al. Recombinant hepatitis B virus surface antigen carrying the pre-S2 region derived from yeast: purification and characterization. J. Biotechnol. 1988, 8:1-21. 10.1016/0168-1656(88)90064-8.
56. Yamada T., Jung J., Seno M., Kondo A., Ueda M., Tanizawa K., et al. Electroporation and use of hepatitis B virus envelope L proteins as bionanocapsules. Cold Spring Harb. Protoc. 2012, 10.1101/pdb.prot069534.
57. Yu D., Amano C., Fukuda T., Yamada T., Kuroda S., Tanizawa K., et al. The specific delivery of proteins to human liver cells by engineered bio-nanocapsules. FEBS J. 2005, 272:3651-3660. 10.1111/j.1742-4658.2005.04790.x.
58. Miyata T., Tafuku S., Harakuni T., Tadano M., Yoshimoto N., Iijima M., et al. A bio-nanocapsule containing envelope protein domain III of Japanese encephalitis virus protects mice against lethal Japanese encephalitis virus infection. Microbiol. Immunol. 2013, 57:470-477. 10.1111/1348-0421.12055.
59. Kaneda Y., Iwai K., Uchida T. Increased expression of DNA cointroduced with nuclear protein in adult rat liver. Science 1989, 243(80-):375-378. 10.1126/science.2911748.
60. Jung J., Matsuzaki T., Tatematsu K., Okajima T., Tanizawa K., Kuroda S. Bio-nanocapsule conjugated with liposomes for in vivo pinpoint delivery of various materials. J. Control. Release 2008, 126:255-264. 10.1016/j.jconrel.2007.12.002.
61. Kasuya T., Jung J., Kinoshita R., Goh Y., Matsuzaki T., Iijima M., et al. Bio-nanocapsule-liposome conjugates for in vivo pinpoint drug and gene delivery. Methods Enzymol. 2009, 464:147-166. 10.1016/S0076-6879(09)64008-8.
62. Somiya M., Yamaguchi K., Liu Q., Niimi T., Maturana Daniel A., Iijima M., et al. One-step scalable preparation method for non-cationic liposomes with high siRNA content. Int. J. Pharm. 2015, 490:316-323. 10.1016/j.ijpharm.2015.05.072.
63. Ohno M., Otsuka M., Kishikawa T., Shibata C. Specific delivery of microRNA93 into HBV-replicating hepatocytes downregulates protein expression of liver cancer susceptible gene MICA. Oncotarget 2014, 5:5581-5590. (www.impactjournals.com/oncotarget/).
64. Katayama Y., Fujii K., Ito E., Sakakihara S., Sonoda T., Murata M., et al. Intracellular signal-responsive artificial gene regulation for novel gene delivery. Biomacromolecules 2002, 3:905-909. 10.1021/bm025532h.
65. Oishi J., Jung J., Tsuchiya A., Toita R., Kang J.H., Mori T., et al. A gene-delivery system specific for hepatoma cells and an intracellular kinase signal based on human liver-specific bionanocapsules and signal-responsive artificial polymer. Int. J. Pharm. 2010, 396:174-178. 10.1016/j.ijpharm.2010.06.012.
66. Kang J.H., Oishi J., Kim J.H., Ijuin M., Toita R., Jun B., et al. Hepatoma-targeted gene delivery using a tumor cell-specific gene regulation system combined with a human liver cell-specific bionanocapsule, Nanomedicine Nanotechnology. Biol. Med. 2010, 6:583-589. 10.1016/j.nano.2010.01.007.
67. Liu Q., Jung J., Somiya M., Iijima M., Yoshimoto N., Tomoaki N., et al. Virosomes of hepatitis B virus envelope L proteins containing doxorubicin: synergistic enhancement of human liver-specific anti-tumor growth activity by radiotherapy. Int. J. Nanomedicine 2015, 10:4159-4172. 10.2147/IJN.S84295.
68. Boussif O., Lezoualc'h F., Zanta M.A., Mergny M.D., Scherman D., Demeneix B., et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:7297-7301. (http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=41326&tool=pmcentrez&rendertype=abstract.).
69. Akinc A., Thomas M., Klibanov A.M., Langer R. Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J. Gene Med. 2005, 7:657-663. 10.1002/jgm.696.
70. Somiya M., Yoshimoto N., Iijima M., Niimi T., Dewa T., Jung J., et al. Targeting of polyplex to human hepatic cells by bio-nanocapsules, hepatitis B virus surface antigen L protein particles. Bioorg. Med. Chem. 2012, 20:3873-3879. 10.1016/j.bmc.2012.04.031.
71. Tsutsui Y., Tomizawa K., Nagita M., Michiue H., Nishiki T.I., Ohmori I., et al. Development of bionanocapsules targeting brain tumors. J. Control. Release 2007, 122:159-164. 10.1016/j.jconrel.2007.06.019.
72. Hamada H., Shimoda K., Seno M. Chemo-enzymatic synthesis of propionyl-ester-linked taxol-monosaccharide conjugate and its drug delivery system using hybrid-bio-nanocapsules targeting brain glioma cells. Clin. Med. Insights Women's Heal. 2013, 6:71. 10.4137/CMWH.S8213.
73. Kurata N., Shishido T., Muraoka M., Tanaka T., Ogino C., Fukuda H., et al. Specific protein delivery to target cells by antibody-displaying bionanocapsules. J. Biochem. 2008, 144:701-707. 10.1093/jb/mvn131.
74. Tacken P.J., de Vries I.J.M., Torensma R., Figdor C.G. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 2007, 7:790-802. 10.1038/nri2173.
75. Matsuo H., Yoshimoto N., Iijima M., Niimi T., Jung J., Jeong S.Y., et al. Engineered hepatitis B virus surface antigen L protein particles for in vivo active targeting of splenic dendritic cells. Int. J. Nanomedicine 2012, 7:3341-3350. 10.2147/IJN.S32813.
76. Iijima M., Somiya M., Yoshimoto N., Niimi T., Kuroda S. Nano-visualization of oriented-immobilized IgGs on immunosensors by high-speed atomic force microscopy. Sci. Rep. 2012, 2:790. 10.1038/srep00790.
77. Iijima M., Kadoya H., Hatahira S., Hiramatsu S., Jung G., Martin A., et al. Nanocapsules incorporating IgG Fc-binding domain derived from Staphylococcus aureus protein A for displaying IgGs on immunosensor chips. Biomaterials 2011, 32:1455-1464. 10.1016/j.biomaterials.2010.10.057.
78. Shishido T., Mieda H., Hwang S.Y., Nishimura Y., Tanaka T., Ogino C., et al. Affibody-displaying bionanocapsules for specific drug delivery to HER2-expressing cancer cells. Bioorg. Med. Chem. Lett. 2010, 20:5726-5731. 10.1016/j.bmcl.2010.08.011.
79. Deshane J., Garner C.C., Sontheimer H. Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2. J. Biol. Chem. 2003, 278:4135-4144. 10.1074/jbc.M205662200.
80. Kasai T., Nakamura K., Vaidyanath A., Chen L., Sekhar S., El-Ghlban S., et al. Chlorotoxin fused to IgG-Fc inhibits glioblastoma cell motility via receptor-mediated endocytosis. J. Drug Deliv. 2012, 2012:975763. 10.1155/2012/975763.
81. Kasuya T., Jung J., Kadoya H., Matsuzaki T., Tatematsu K., Okajima T., et al. In vivo delivery of bionanocapsules displaying Phaseolus vulgaris agglutinin-L4 isolectin to malignant tumors overexpressing N-acetylglucosaminyltransferase V. Hum. Gene Ther. 2008, 19:887-895. 10.1089/hum.2008.037.
82. Shishido T., Azumi Y., Nakanishi T., Umetsu M., Tanaka T., Ogino C., et al. Biotinylated bionanocapsules for displaying diverse ligands toward cell-specific delivery. J. Biochem. 2009, 146:867-874. 10.1093/jb/mvp134.
83. Shishido T., Yonezawa D., Iwata K., Tanaka T., Ogino C., Fukuda H., et al. Construction of arginine-rich peptide displaying bionanocapsules. Bioorg. Med. Chem. Lett. 2009, 19:1473-1476. 10.1016/j.bmcl.2009.01.049.
84. Khalil I.A., Kogure K., Akita H., Harashima H. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol. Rev. 2006, 58:32-45. 10.1124/pr.58.1.8.32.
85. Nishimura Y., Takeda K., Ezawa R., Ishii J., Ogino C., Kondo A. A display of pH-sensitive fusogenic GALA peptide facilitates endosomal escape from a Bio-nanocapsule via an endocytic uptake pathway. J. Nanobiotechnol. 2014, 12:11. 10.1186/1477-3155-12-11.
86. Seow Y., Wood M.J. Biological gene delivery vehicles: beyond viral vectors. Mol. Ther. 2009, 17:767-777. 10.1038/mt.2009.41.
87. Ludwig C., Wagner R. Virus-like particles-universal molecular toolboxes. Curr. Opin. Biotechnol. 2007, 18:537-545. 10.1016/j.copbio.2007.10.013.
88. Touze A., Coursaget P. In vitro gene transfer using human papillomavirus-like particles. Nucleic Acids Res. 1998, 26:1317-1323. 10.1093/nar/26.5.1317.
89. Kanesashi S.N., Ishizu K.I., Kawano M.A., Han S.I., Tomita S., Watanabe H., et al. Simian virus 40 VP1 capsid protein forms polymorphic assemblies in vitro. J. Gen. Virol. 2003, 84:1899-1905. 10.1099/vir.0.19067-0.
90. Enomoto T., Kukimoto I., Kawano M.A., Yamaguchi Y., Berk A.J., Handa H. In vitro reconstitution of SV40 particles that are composed of VP1/2/3 capsid proteins and nucleosomal DNA and direct efficient gene transfer. Virology 2011, 420:1-9. 10.1016/j.virol.2011.08.014.
91. Inoue T., Kawano M.A., Takahashi R.U., Tsukamoto H., Enomoto T., Imai T., et al. Engineering of SV40-based nano-capsules for delivery of heterologous proteins as fusions with the minor capsid proteins VP2/3. J. Biotechnol. 2008, 134:181-192. 10.1016/j.jbiotec.2007.12.006.
92. Kitai Y., Fukuda H., Enomoto T., Asakawa Y., Suzuki T., Inouye S., et al. Cell selective targeting of a simian virus 40 virus-like particle conjugated to epidermal growth factor. J. Biotechnol. 2011, 155:251-256. 10.1016/j.jbiotec.2011.06.030.
93. Almeida J.D., Edwards D.C., Brand C.M., Heath T.D. Formation of virosomes from influenza subunits and liposomes. Lancet 1975, 306:899-901. (http://www.sciencedirect.com/science/article/pii/S0140673675921303 (accessed January 6, 2012)).
94. Felnerova D., Viret J.F., Glück R., Moser C. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr. Opin. Biotechnol. 2004, 15:518-529. 10.1016/j.copbio.2004.10.005.
95. Glück R., Mischler R., Brantschen S., Just M., Althaus B., Cryz S.J. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J. Clin. Invest. 1992, 90:2491-2495. 10.1172/JCI116141.
96. Waelti E., Wegmann N., Schwaninger R., Wetterwald A., Wingenfeld C., Rothen-Rutishauser B., et al. Targeting HER-2/neu with antirat neu virosomes for cancer therapy. Cancer Res. 2002, 62:437-444.
97. Kaneda Y. Virosome: a novel vector to enable multi-modal strategies for cancer therapy. Adv. Drug Deliv. Rev. 2012, 64:730-738. 10.1016/j.addr.2011.03.007.
98. Toita R., Murata M., Abe K., Narahara S., Piao J.S., Kang J.H., et al. Biological evaluation of protein nanocapsules containing doxorubicin. Int. J. Nanomedicine 2013, 8:1989-1999. 10.2147/IJN.S40239.
99. Zhen Z., Tang W., Chen H., Lin X., Todd T., Wang G., et al. RGD-modified apoferritin nanoparticles for efficient drug delivery to tumors. ACS Nano 2013, 7:4830-4837. 10.1021/nn305791q.
100. Murata M., Narahara S., Umezaki K., Toita R., Tabata S., Piao J.S., et al. Liver cell specific targeting by the preS1 domain of hepatitis B virus surface antigen displayed on protein nanocages. Int. J. Nanomedicine 2012, 7:4353-4362. 10.2147/IJN.S31365.
101. Murata M., Piao J.S., Narahara S., Kawano T., Hamano N., Kang J.-H., et al. Expression and characterization of myristoylated preS1-conjugated nanocages for targeted cell delivery. Protein Expr. Purif. 2014, 10.1016/j.pep.2014.12.001.
102. 2 nanoparticles for use with ultrasound irradiation in a novel cell injuring method. Bioorg. Med. Chem. Lett. 2010, 20:5320-5325. 10.1016/j.bmcl.2010.06.124.
103. Ninomiya K., Ogino C., Oshima S., Sonoke S., Kuroda S.I., Shimizu N. Targeted sonodynamic therapy using protein-modified TiO 2 nanoparticles. Ultrason. Sonochem. 2012, 19:607-614. 10.1016/j.ultsonch.2011.09.009.
104. Zhang X., Zhang Q., Peng Q., Zhou J., Liao L., Sun X., et al. Hepatitis B virus preS1-derived lipopeptide functionalized liposomes for targeting of hepatic cells. Biomaterials 2014, 35:6130-6141. 10.1016/j.biomaterials.2014.04.037.
105. Hama S., Akita H., Ito R., Mizuguchi H., Hayakawa T., Harashima H. Quantitative comparison of intracellular trafficking and nuclear transcription between adenoviral and lipoplex systems. Mol. Ther. 2006, 13:786-794. 10.1016/j.ymthe.2005.10.007.
106. Hyodo M., Sakurai Y., Akita H., Harashima H. "Programmed packaging" for gene delivery. J. Control. Release 2014, 193:316-323. 10.1016/j.jconrel.2014.04.023.
107. Ara M.N., Matsuda T., Hyodo M., Sakurai Y., Hatakeyama H., Ohga N., et al. An aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells. Biomaterials 2014, 35:7110-7120. 10.1016/j.biomaterials.2014.04.087.
108. Khalil I.A., Kogure K., Futaki S., Hama S., Akita H., Ueno M., et al. Octaarginine-modified multifunctional envelope-type nanoparticles for gene delivery. Gene Ther. 2007, 14:682-689. 10.1038/sj.gt.3302910.
109. Kusumoto K., Akita H., Santiwarangkool S., Harashima H. Advantages of ethanol dilution method for preparing GALA-modified liposomal siRNA carriers on the in vivo gene knockdown efficiency in pulmonary endothelium. Int. J. Pharm. 2014, 473:144-147. 10.1016/j.ijpharm.2014.07.007.
110. Mastrobattista E., van der AA M.A.E.M., Hennink W.E., Crommelin D.J.A. Artificial viruses: a nanotechnological approach to gene delivery. Nat. Rev. Drug Discov. 2006, 5:115-121. 10.1038/nrd1960.
111. Nishimura Y., Mieda H., Ishii J., Ogino C., Fujiwara T., Kondo A. Targeting cancer cell-specific RNA interference by siRNA delivery using a complex carrier of affibody-displaying bio-nanocapsules and liposomes. J. Nanobiotechnol. 2013, 11:19. 10.1186/1477-3155-11-19.